• MICHAEL CALIGIURI (Chair), Chief Executive Officer, James Cancer Hospital and Solove Research Institute; Director, Ohio State University Comprehensive Cancer Center
• PATRICIA A. GANZ (Vice Chair), Distinguished Professor, Health Policy & Management and Medicine, University of California, Los Angeles (UCLA) Fielding School of Public Health, David Geffen School of Medicine at UCLA; Director, Cancer Prevention and Control Research, UCLA Jonsson Comprehensive Cancer Center
• AMY P. ABERNETHY, Chief Medical Officer and Senior Vice President for Oncology, Flatiron Health; Professor, Division of Medical Oncology, Duke University School of Medicine; Director, Center for Learning Health Care, Duke Clinical Research Institute
• LUCILE ADAMS-CAMPBELL, Professor of Oncology, Associate Director for Minority Health and Health Disparities Research, Georgetown University Lombardi Cancer Center
• KENNETH ANDERSON, Kraft Family Professor of Medicine, American Cancer Society Clinical Research Director, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute
• LOYCE PACE BASS, Health Policy Director, LIVESTRONG Foundation
• MONICA BERTAGNOLLI, Professor of Surgery, Harvard University Medical School
• OTIS BRAWLEY, Chief Medical Officer and Executive Vice President, American Cancer Society
• CARLTON BROWN, Director of Professional Services, Oregon Nurses Association, and past president, Oncology Nursing Society
• SERGIO CANTOREGGI, Chief Scientific Officer and Global Head of Research and Development, Helsinn Group
• ROBERT W. CARLSON, Chief Executive Officer, National Comprehensive Cancer Network
• GREGORY CURT, Executive Director for External Relations in US Medical Affairs, AstraZeneca; Co-Chair, Life Sciences Consortium Task Force
• WILLIAM S. DALTON, Chief Executive Officer, M2Gen Personalized Medicine Institute, Moffitt Cancer Center; Chair, American Association for Cancer Research Science Policy & Legislative Affairs Committee
• GWEN DARIEN, Executive Vice President, Programs and Services, Cancer Policy Institute, Cancer Support Community
• WENDY DEMARK-WAHNEFRIED, Associate Director for Cancer Prevention and Control, University of Alabama at Birmingham Comprehensive Cancer Center
• JAMES DOROSHOW, Director, Division of Cancer Treatment and Diagnosis, Deputy Director, Clinical and Translational Research, National Cancer Institute
• CAROL A. HAHN, Associate Professor of Radiation Oncology, Duke University Medical Center; Medical Director of Radiation Oncology, Duke Raleigh Hospital; Clinical Affairs and Quality Council Chair, American Society for Radiation Oncology
• LORI HOFFMAN HŌGG, Veterans Health Administration National Oncology Clinical Advisor, Office of Nursing Services; Cancer Program Director, Albany Stratton Veterans Affairs Medical Center
• SAMIR N. KHLEIF, Director, Georgia Health Sciences University Cancer Center, Georgia Regents University Cancer Center
• LEE KRUG, Disease Area Head, Immuno-Oncology, Bristol-Myers Squibb
• RICHARD A. LARSON, Hematology/Oncology Director, University of Chicago
• MICHELLE M. LE BEAU, Arthur and Marian Edelstein Professor of Medicine, Director, Comprehensive Cancer Center, University of Chicago
• SHARI LING, Deputy Chief Medical Officer, Center for Clinical Standards and Quality, Centers for Medicare & Medicaid Services
• GRETA MASSETTI, Associate Director for Science, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention
• DANIEL R. MASYS, Affiliate Professor, Biomedical Informatics, University of Washington
• MARTIN J. MURPHY, Chief Executive Officer, CEO Roundtable on Cancer
• RICHARD PAZDUR, Director, Office of Oncology and Hematology Products, Food and Drug Administration
• STEVEN PIANTADOSI, Phase One Foundation Endowed Chair and Director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
• JENNIFER A. PIETENPOL, Director, Vanderbilt-Ingraham Cancer Center, Benjamin F. Byrd, Jr., Professor of Oncology, Professor of Biochemistry, Vanderbilt University
• MACE L. ROTHENBERG, Chief Medical Officer & Senior Vice President, Clinical Development & Medical Affairs, Pfizer Oncology
• AUGUST SALVADO, Senior Vice President, US Oncology Clinical Development & Medical Affairs, Novartis Oncology
• ANDREW SCHIERMEIER, Senior Vice President, Head of Global Oncology, Merck Serono
• RICHARD SCHILSKY, Chief Medical Officer, American Society of Clinical Oncology
• DEBORAH SCHRAG, Chief, Division of Population Sciences, Professor of Medicine, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
• YA-CHEN TINA SHIH, Professor of Health Economics, Chief, Section of Cancer Economics and Policy, Department of Health Services Research, University of Texas MD Anderson Cancer Center
• ELLEN V. SIGAL, Chair and Founder, Friends of Cancer Research
• RALPH WEICHSELBAUM, Daniel K. Ludwig Professor and Chair, Department of Radiation Oncology; Director, Ludwig Center for Metastasis Research, The University of Chicago Medical Center
• GEORGE J. WEINER, Director, Holden Comprehensive Cancer Center, University of Iowa, President, Association of American Cancer Institutes

Footnotes

1

Institute of Medicine forums and roundtables do not issue, review, or approve individual documents. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.